Showing results (21-30 of 59) with videos related to
Sort By:
Pageof 6
Toxicon : Official Journal of the International Society on Toxinology|July 20, 2019
The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A productsAnna Kutschenko, Hans Bigalke, Florian Wegner, et al.Therapeutic Advances in Neurological Disorders|January 4, 2020
Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystoniaHarald Hefter, Dietmar Rosenthal, Hans Bigalke, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|June 7, 2019
Do complexing proteins provide mechanical protection for botulinum neurotoxins?Dirk Dressler, Lizhen Pan, Fereshte Adib Saberi, et al.Journal of Molecular Biology|February 13, 2003
Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicityAndreas Rummel, Steffen Bade, Jürgen Alves, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|November 11, 2019
Comparing lanbotulinumtoxinA (Hengli<sup>®</sup>) with onabotulinumtoxinA (Botox<sup>®</sup>) and incobotulinumtoxinA (Xeomin<sup>®</sup>) in the mouse hemidiaphragm assayLizhen Pan, Hans Bigalke, Bruno Kopp, et al.Annals of Neurology|July 12, 2002
Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodiesFrank Birklein, Dirk Walther, Hans Bigalke, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|March 26, 2009
Experience with long-term treatment with albumin-supplemented botulinum toxin type ABahram Mohammadi, Katja Kollewe, Maresa Wegener, et al.The Journal of Biological Chemistry|May 5, 2004
Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin GAndreas Rummel, Tino Karnath, Tina Henke, et al.FEBS Letters|March 21, 2006
The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nervesStefan Mahrhold, Andreas Rummel, Hans Bigalke, et al.BMJ Open|August 7, 2012
Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins--a single cohort 4-year follow-up studyHarald Hefter, Christian Hartmann, Ulrike Kahlen, et al.Pageof 6